TrialBreast cancer research and treatment2026

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Norikazu Masuda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.